| Note: this study is at multiple sites in North Carolina |
| Study title |
Viking: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF VK2809 ADMINISTERED FOR 52 WEEKS IN SUBJECTS WITH BIOPSY PROVEN NASH WITH FIBROSIS |
| Disease or condition |
NAFLD/NASH with Fibrosis |
| Study type |
Interventional (Clinical Trial) |
| Intervention/treatment |
VK2809 or Placebo |
| Phase |
2 |
| Study site 1 |
Duke University |
| Study location |
Durham, NC |
| Principal investigator |
Manal Abdelmalek, MD; manal.abdelmalek@duke.edu |
| Study coordinator |
Angie Shenouda; angie.shenouda@duke.edu |
| Phone contact |
(919) 613-8802 |
| Study site 2 |
Carolinas Medical Center, Center for Liver Disease and Transplant (Atrium Health) |
| Study location |
Charlotte, NC |
| Principal investigator |
Andrew deLemos, MD |
| Study coordinator |
Marina Sycheva, marina.sycheva@atriumhealth.org |
| Phone Contact |
704-446-4835 |
| Clinicaltrials.gov link |
https://clinicaltrials.gov/ct2/show/NCT04173065 |
